Taibei, China – Recently, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") received the regulatory approval from Taiwan Food and Drug Administration ("TFDA") for its in-house developed Firebird2® Rapamycin-Eluting Coronary CoCr Stent System ("Firebird2®"). It is the second drug-eluting stent of MicroPort® that successfully gained the regulatory approval in Taiwan, following Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®").
Firebird2® is the second generation drug-eluting stent of MicroPort® for the treatment of coronary artery stenosis or occlusion. It is based on the new cobalt chromium alloy stent platform. It has good radial support force, excellent stent flexibility, and outstanding MRI compatibility.
With the increasing aging population, the incidence rate of coronary disease is constantly growing in Taiwan. According to statistics, there are around 30,000 PCI cases in the Taiwan market annually and the demand for coronary stent is rapidly increasing. As Firehawk® and Firebird2® both gained regulatory approval in Taiwan, MicroPort® further diversified its product offering in the local market. With its outstanding performance, it is expected that Firebird2® will provide more ideal cardiovascular treatment for the local patients.